Head to head
Eden vs Willow
Both are real, operating US telehealth companies. What separates them is what they supply, what they charge for it, and what regulators have published about each — all of it below, linked to the primary documents.
- Eden
- Both
Not published - Willow
- Compounded
$299/mo - Eden on file
- 1
- Willow on file
- 3
Side by side
What each one publishes about itself
Every figure here is the provider’s own advertised number, not an estimate. A dash means the company does not publish it.
| Eden | Willow | |
|---|---|---|
| Supplies | Compounded and branded | Compounded only |
| Advertised from | Not published | $299/mo |
| First month | $99 | — |
| Medication in the price | Included | Included |
| Insurance | Cash pay | Cash pay |
| Intake | Async | Async |
| On the record | 1 action | 3 actions |
The difference that actually matters
Eden: Supplies both compounded medication and FDA-approved branded drugs, usually at very different prices. Check which one a quoted price refers to. Willow: Supplies compounded semaglutide or tirzepatide — medication prepared by a compounding pharmacy, not an FDA-approved product. Cheaper, legal, and the category the FDA has been issuing warning letters about.
What is on Eden’s record
2026-06
FDA warning letter to Eden Health International, Inc. dba Eden (MARCS-CMS 728279).
What is on Willow’s record
2025-12
The National Advertising Division, on a challenge by Novo Nordisk, recommended on 4 December 2025 that Willow Health Services discontinue or modify health claims for its compounded semaglutide products. Willow declined to provide a compliance statement, and NAD referred the matter to regulatory authorities and to the platforms carrying the advertising.
2026-07
Reopened NAD matter closed after Willow Health Services voluntarily discontinued claims that its compounded semaglutide was proven to support weight loss, delivered results comparable to FDA-approved semaglutide, and produced effective weight loss without diet or exercise.
2026-02
Eli Lilly sued Willow Health Services, Inc. in the Central District of California on 23 April 2025 (No. 2:25-cv-03570) over compounded tirzepatide. The case was dismissed with prejudice on 3 February 2026 for failure to establish Lanham Act standing — the court held the prescribing physician, not Willow's advertising, was the proximate cause of any lost sales — with no ruling on whether the marketing was misleading. Lilly has appealed to the Ninth Circuit (No. 26-1317).
Go direct
Both companies, and what we earn from each
We do not recommend one over the other. Where a link pays us, it says so here and on the provider’s own page.
Eden
Compounded and branded, price not published. 1 action on record, each linked on its page. The link below earns us nothing.
Willow
Compounded only, from $299 a month. 3 actions on record, each linked on its page. The link below is an affiliate link and pays us a commission; it changed nothing above.
Straight answers
Eden vs Willow, in short
- Is Eden or Willow cheaper?
- At least one of the two does not publish a starting price, so the honest answer is that they cannot be compared on cost from public information alone. What each supplies is on the record above.
- What is the difference between Eden and Willow?
- Eden: both compounded and FDA-approved medication. Willow: compounded medication only. One of the two sells both categories, so its advertised headline price almost certainly refers to the compounded option.
- Which one has more regulatory actions on record?
- Willow, with 3 sourced actions against 1 action for Eden. Every one is linked to its primary document on the provider's own page. A larger file is not automatically a worse company — read what the documents actually say.
Other comparisons: Henry Meds vs Willow · Mochi Health vs Willow · Eden vs Zealthy · Willow vs TrimRx